


Substitute Form PTO-1595
 Attorney Docket No.: 14878-018001 and 018002
 Client's Ref. No.: D1-702PCT-US



RECORDATION FORM COVER SHEET PATENTS ONLY

Commissioner for Patents: Please record the attached original document(s) or copy(ies).					
1. Name of conveying party(ies): <p style="text-align: center;">Fujisawa Pharmaceutical Co., Ltd.</p> Additional name(s) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies): <p style="text-align: center;">Astellas Pharma, Inc. 3-11, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo 103-8411 Japan</p> Additional names/addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
3. Nature of conveyance: <input type="checkbox"/> Assignment <input checked="" type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other. Execution Date: 10/24/05 (Commercial Register of Astellas Pharma, Inc)					
4. Application number(s) or patent number(s): If this document is being filed with a new application, the execution date of the application is: <table style="width: 100%;"> <tr> <td style="width: 50%;">A. Patent Application No(s).:</td> <td style="width: 50%;">B: Patent No(s).:</td> </tr> <tr> <td></td> <td style="text-align: center;">6,166,219 6,352,985</td> </tr> </table> Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		A. Patent Application No(s).:	B: Patent No(s).:		6,166,219 6,352,985
A. Patent Application No(s).:	B: Patent No(s).:				
	6,166,219 6,352,985				
5. Name/address of party to whom correspondence concerning document should be mailed: <p style="text-align: center;">JANIS K. FRASER, PH.D., J.D. Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110</p>	6. Total number of applications/patents involved: 1 7. Total fee (37 CFR §3.41): \$80 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to charge Deposit Account. 8. Deposit Account No.: 06-1050 Please apply any additional charges, or any credits, to our Deposit Account No. 06-1050.				
DO NOT USE THIS SPACE					
9. Statement and Signature: <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>					
Timothy A. French Reg. No. 30,175 Name of Person Signing	 Signature				
	Date <u>April 11, 2006</u>				
Total number of pages including coversheet, attachments and document: 21					

21290890.doc

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

<u>4/11/06</u> Date of Transmission	 Signature	 Typed Name of Person Signing Certificate
--	--	---

PATENT

700257457

REEL: 017468 FRAME: 0325

CH \$80.00 061050 6166219

STATEMENT

Assistant Commissioner for Patents
Alexandria, VA 22313-1450

Sir/Madam:

I, Katsunobu Ihara, of which postal address is ARK MORI BLDG, 13F,
12-32, Akasaka 1-chome, Minato-ku, Tokyo, Japan hereby state that:

I well understand the Japanese and English languages and attached is
an accurate English translation made by me of the certified copy of the
commercial register (Certificate of All the Records Registered) of Astellas Pharma
Inc.

Date : Dec. 12, 2005 Name : 井原 克誠
Katsunobu IHARA

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Certificate of All the Records Registered

Trade name	<u>Yamanouchi Pharmaceutical Co., Ltd.</u>	
	Astellas Pharma Inc.	Changed April 1, 2005 Registered April 1, 2005
Location of head office	3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo	
Method of public notice	The statement is executed by publication in the <i>Nihon Keizai Shimbun</i> issued in Tokyo.	
Matters necessary for obtaining information relating to the balance sheet	<u>http://www.yamanouchi.com/jp/index.html</u>	Established March 25, 2003 Registered April 1, 2003
	<u>http://www.astellas.com/jp</u>	Changed April 1, 2005 Registered April 1, 2005
Date of incorporation	March 20, 1939	
Object	<ol style="list-style-type: none"> 1. <u>Manufacture, sale, import and export of pharmaceuticals, quasi-drugs, drugs used for animals, industrial chemicals, agricultural chemicals and other chemical products</u> 2. <u>Manufacture, sale, import and export of foods, food additives, seasonings, livestock feeds, feed additives, cosmetics, sanitary fixtures, medical instruments, meters and gauges, daily necessities and miscellaneous goods</u> 3. <u>Manufacture, sale, import and export of medical machines and equipment, industrial machines and equipment and household equipment</u> 4. <u>Manufacture, sale, import and export of alcoholic beverages and other beverages</u> 5. <u>Breeding, sale, import and export of laboratory animals</u> 6. <u>Sale, purchase, lease, and management of real estate and agency business thereof</u> 7. <u>Warehouse business and road transport business</u> 8. <u>Hotel business, and management and control of health and physical education facilities and equipment</u> 9. <u>Casualty insurance agency business</u> 10. <u>Information processing service business using computer</u> 11. <u>All businesses incidental to or related to one of the preceding items</u> <ol style="list-style-type: none"> 1. Manufacture, sale, import and export of pharmaceuticals, quasi-drugs, drugs used for animals, reagents, industrial chemicals, agricultural chemicals and other chemical products 2. Manufacture, sale, import and export of foods, food additives, seasonings, fertilizers, livestock feeds, feed additives, cosmetics, sanitary fixtures, medical instruments, medical instruments used for animals, meters and gauges, daily necessities and miscellaneous goods 3. Sale, purchase, import and export of natural products 4. Lease and maintenance of medical instruments 5. Manufacture, sale, import, export, lease and maintenance of medical machines and equipment, industrial machines and equipment and household equipment 6. Scientific inspections related to medical treatment 7. Manufacture, sale, import and export of liquors, alcoholic beverages and other beverages 8. Breeding, sale, import and export of laboratory animals 9. Sale, purchase, lease, and management of real estate and agency business thereof 10. Warehouse business, road transport business and freight transport business 	

PATENT

REEL: 017468 FRAME: 0327

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

	11. Hotel business, and management and control of health and physical education facilities and equipment 12. Casualty insurance agency business 13. Publishing business 14. Sale, lease and maintenance of computer 15. Development, sale and lease of computer software 16. Information processing and information service business using computer 17. Management consulting business 18. All businesses incidental to or related to one of the preceding Items Changed April 1, 2005, and registered April 1, 2005	
Number of shares of one unit	<u>1,000 shares</u>	
	100 shares	Changed April 1, 2002 Registered April 2, 2002
Total number of shares authorized to be issued	<u>800 million shares</u>	
	2 billion shares	Registered April 1, 2005
Total number of shares issued giving type of stock and number of shares of each type	Total number of issued shares	Changed April 30, 2001
	<u>361,152,522 shares</u>	Registered May 9, 2001
	Total number of issued shares	Changed February 28, 2002
	<u>361,203,052 shares</u>	Registered March 11, 2002
	Total number of issued shares	Changed April 30, 2002
	<u>361,203,604 shares</u>	Registered May 10, 2002
	Total number of issued shares	Changed May 31, 2002
	<u>361,214,262 shares</u>	Registered June 12, 2002
	Total number of issued shares	Changed December 30, 2002
	<u>361,216,470 shares</u>	Registered January 14, 2003
	Total number of issued shares	Changed April 30, 2004
	<u>361,221,523 shares</u>	Registered May 13, 2004
	Total number of issued shares	Changed October 31, 2004
	<u>361,549,971 shares</u>	Registered November 10, 2004
	Total number of issued shares	Changed January 31, 2005
	<u>361,954,215 shares</u>	Registered February 8, 2005
Amount of capital	Total number of issued shares	Registered April 1, 2005
	<u>571,428,003 shares</u>	Changed April 30, 2005
	Total number of issued shares	Registered May 13, 2005
	<u>571,695,814 shares</u>	Changed June 30, 2005
	Total number of issued shares	Registered July 12, 2005
	<u>572,074,792 shares</u>	Changed September 30, 2005
	Total number of issued shares	Registered October 13, 2005
	<u>573,949,476 shares</u>	Changed April 30, 2001
	<u>¥99,694,563,841</u>	Registered May 9, 2001
		Changed February 28, 2002
	<u>¥99,744,563,841</u>	Registered March 11, 2002
		Changed April 30, 2002
	<u>¥99,745,563,513</u>	Registered May 10, 2002
		Changed May 31, 2002
	<u>¥99,756,563,185</u>	Registered June 12, 2002
		Changed December 30, 2002
	<u>¥99,760,561,873</u>	Registered January 14, 2003

PATENT

REEL: 017468 FRAME: 0328

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

	<u>¥99,765,561,873</u>	Changed April 30, 2004 Registered May 13, 2004
	<u>¥100,090,561,873</u>	Changed October 31, 2004 Registered November 10, 2004
	<u>¥100,490,561,873</u>	Changed January 31, 2005 Registered February 8, 2005
	<u>¥100,755,561,873</u>	Changed April 30, 2005 Registered May 13, 2005
	<u>¥101,130,561,873</u>	Changed June 30, 2005 Registered July 12, 2005
	<u>¥102,985,561,873</u>	Changed September 30, 2005 Registered October 13, 2005
Name, address, and place of business of transfer agent	33-1, Shiba 3-chome, Minato-ku, Tokyo The Chuo Mitsui Trust and Banking Company, Limited 33-1, Shiba 3-chome, Minato-ku, Tokyo Head Office, The Chuo Mitsui Trust and Banking Company, Limited Changed December 4, 2000, and registered December 8, 2000	
Matters relating to officers	<u>Director</u> <u>Masayoshi Onoda</u>	Reappointed June 28, 2001 Registered July 10, 2001 Retired June 27, 2003 Registered July 11, 2003
	<u>Director</u> <u>Toichi Takenaka</u>	Reappointed June 28, 2001 Registered July 10, 2001
	<u>Director</u> <u>Toichi Takenaka</u>	Reappointed June 27, 2003 Registered July 11, 2003 Resigned March 31, 2005 Registered April 1, 2005
	<u>Director</u> <u>Kaoru Kimura</u>	Reappointed June 28, 2001 Registered July 10, 2001 Retired June 27, 2003 Registered July 11, 2003
	<u>Director</u> <u>Munetoshi Kakitani</u>	Reappointed June 28, 2001 Registered July 10, 2001 Retired June 27, 2003 Registered July 11, 2003
	<u>Director</u> <u>Nobuji Takayama</u>	Reappointed June 28, 2001 Registered July 10, 2001
	<u>Director</u> <u>Nobuji Takayama</u>	Reappointed June 27, 2003 Registered July 11, 2003 Resigned March 31, 2005 Registered April 1, 2005
	<u>Director</u> <u>Kiyoshi Kawaishi</u>	Reappointed June 29, 2000 Registered July 12, 2000 Retired June 27, 2002 Registered July 10, 2002
	<u>Director</u> <u>Hidehiko Ueda</u>	Reappointed June 29, 2000 Registered July 12, 2000
	<u>Director</u> <u>Hidehiko Ueda</u>	Reappointed June 27, 2002 Registered July 10, 2002 Retired June 24, 2004 Registered July 7, 2004

PATENT

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

	<u>Director</u> <u>Hiroshi Suzuki</u>	Reappointed June 29, 2000
		Registered July 12, 2000
		Retired June 27, 2002
		Registered July 10, 2002
	<u>Director</u> <u>Youzou Noura</u>	Reappointed June 29, 2000
		Registered July 12, 2000
		Retired June 27, 2002
		Registered July 10, 2002
	<u>Director</u> <u>Masakatsu Inoue</u>	Reappointed June 29, 2000
		Registered July 12, 2000
		Retired June 27, 2002
		Registered July 10, 2002
	<u>Director</u> <u>Toshinari Tamura</u>	Reappointed June 29, 2000
		Registered July 12, 2000
	<u>Director</u> <u>Toshinari Tamura</u>	Reappointed June 27, 2002
		Registered July 10, 2002
	<u>Director</u> <u>Toshinari Tamura</u>	Reappointed June 24, 2004
		Registered July 7, 2004
		Resigned March 31, 2005
		Registered April 1, 2005
	<u>Director</u> <u>Kunihide Ichikawa</u>	Reappointed June 29, 2000
		Registered July 12, 2000
	<u>Director</u> <u>Kunihide Ichikawa</u>	Reappointed June 27, 2002
		Registered July 10, 2002
	<u>Director</u> <u>Kunihide Ichikawa</u>	Reappointed June 24, 2004
		Registered July 7, 2004
		Resigned March 31, 2005
		Registered April 1, 2005
	<u>Director</u> <u>Shigekazu Takahashi</u>	Reappointed June 28, 2001
		Registered July 10, 2001
	<u>Director</u> <u>Shigekazu Takahashi</u>	Reappointed June 27, 2003
		Registered July 11, 2003
		Resigned June 24, 2004
		Registered July 7, 2004
	<u>Director</u> <u>Kazuovoshi Hatanaka</u>	Appointed June 29, 2000
		Registered July 12, 2000
	<u>Director</u> <u>Kazuovoshi Hatanaka</u>	Reappointed June 27, 2002
		Registered July 10, 2002
		Retired June 24, 2004
		Registered July 7, 2004
	<u>Director</u> <u>Yasuo Ishii</u>	Appointed June 29, 2000
		Registered July 12, 2000
	<u>Director</u> <u>Yasuo Ishii</u>	Reappointed June 27, 2002
		Registered July 10, 2002
		Retired June 24, 2004
		Registered July 7, 2004
	<u>Director</u> <u>Toshio Saba</u>	Appointed June 28, 2001
		Registered July 10, 2001
	<u>Director</u> <u>Toshio Saba</u>	Reappointed June 27, 2003
		Registered July 11, 2003

PATENT

REEL: 017468 FRAME: 0330

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

		Resigned June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Isao Kishi</u>	Appointed June 28, 2001
		Registered July 10, 2001
<u>Director</u>	<u>Isao Kishi</u>	Reappointed June 27, 2003
		Registered July 11, 2003
		Resigned June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Hiroaki Hiraiwa</u>	Appointed June 28, 2001
		Registered July 10, 2001
<u>Director</u>	<u>Hiroaki Hiraiwa</u>	Reappointed June 27, 2003
		Registered July 11, 2003
		Resigned June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Isao Yanagisawa</u>	Appointed June 28, 2001
		Registered July 10, 2001
<u>Director</u>	<u>Isao Yanagisawa</u>	Reappointed June 27, 2003
		Registered July 11, 2003
<u>Director</u>	<u>Isao Yanagisawa</u>	Family name of Isao Yanagisawa
		Modified March 19, 2004
		Resigned June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Shinji Usuda</u>	Appointed June 27, 2002
		Registered July 10, 2002
		Retired June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Ikuya Sugisaki</u>	Appointed June 27, 2002
		Registered July 10, 2002
		Retired June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Hajime Nakajima</u>	Appointed June 27, 2002
		Registered July 10, 2002
		Retired June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Iwaki Miyazaki</u>	Appointed June 27, 2003
		Registered July 11, 2003
		Resigned June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Kouji Yoshinaga</u>	Appointed June 27, 2003
		Registered July 11, 2003
		Resigned June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Tadao Hasegawa</u>	Appointed June 27, 2003
		Registered July 11, 2003
		Resigned June 24, 2004
		Registered July 7, 2004
<u>Director</u>	<u>Makoto Matsuo</u> (is an outside director)	Appointed June 24, 2004
		Registered July 7, 2004
		Resigned March 31, 2005
		Registered April 1, 2005

PATENT

REEL: 017468 FRAME: 0331

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Director	Hatsuo Aoki	Appointed April 1, 2005
		Registered April 1, 2005
Director	Toichi Takenaka	Appointed April 1, 2005
		Registered April 1, 2005
Director	Toshinari Tamura	Appointed April 1, 2005
		Registered April 1, 2005
Director	Masafumi Nogimori	Appointed April 1, 2005
		Registered April 1, 2005
Director	<u>Kunihide Ichikawa</u>	Appointed April 1, 2005
		Registered April 1, 2005
		Resigned June 24, 2005
Director	Koichi Sejima	Registered June 29, 2005
		Appointed April 1, 2005
Director	Akiro Kojima (is an outside director)	Registered April 1, 2005
		Appointed April 1, 2005
Director	Makoto Matsuo (is an outside director)	Registered April 1, 2005
		Appointed April 1, 2005
Director	Toshio Saba	Registered June 29, 2005
		Appointed June 24, 2005
Director	Takashi Yamane (is an outside director)	Registered June 29, 2005
		Appointed June 24, 2005
Representative Director	<u>Masayoshi Onoda</u> <u>931-35, Nonoshita 3-chome,</u> <u>Nagareyama-shi, Chiba</u>	Reappointed June 28, 2001
		Registered July 10, 2001
		Resigned June 27, 2002
		Registered July 10, 2002
Representative Director	<u>Toichi Takenaka</u> <u>505-56, Matsugaoka 4-chome,</u> <u>Nagareyama-chi, Chiba</u>	Reappointed June 28, 2001
		Registered July 10, 2001
Representative Director	<u>Toichi Takenaka</u> <u>34-1-1405, Shiba 3-chome, Minato-ku,</u> <u>Tokyo</u>	Changed address March 10, 2003
		Registered March 17, 2003
Representative Director	<u>Toichi Takenaka</u> <u>34-1-1405, Shiba 3-chome, Minato-ku,</u> <u>Tokyo</u>	Reappointed June 27, 2003
		Registered July 11, 2003
		Retired March 31, 2005
		Registered April 1, 2005
Representative Director	<u>Hidehiko Ueda</u> <u>3-2-1202, Nihonbashi Hamacho 2-chome,</u> <u>Chuo-ku, Tokyo</u>	Appointed June 27, 2003
		Registered July 11, 2003
		Retired June 24, 2004
		Registered July 7, 2004
Representative Director	<u>Toshinari Tamura</u> <u>21-10, Midoricho 1-chome, Hasuda-shi,</u> <u>Saitama</u>	Appointed October 1, 2004
		Registered October 1, 2004
		Retired March 31, 2005
		Registered April 1, 2005

PATENT

REEL: 017468 FRAME: 0332

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Representative Director	<u>Hatsuo Aoki</u> 13-3, Hata 4-chome, Ikeda-shi, Osaka	Appointed April 1, 2005
		Registered April 1, 2005
Representative Director	<u>Toichi Takenaka</u> 34-1-1405, Shiba 3-chome, Minato-ku, Tokyo	Appointed April 1, 2005
		Registered April 1, 2005
Representative Director	<u>Toshinari Tamura</u> 21-10, Midoricho 1-chome, Hasuda-shi, Saitama	Appointed April 1, 2005
		Registered April 1, 2005
Representative Director	<u>Masafumi Nogimori</u> 65-2, Makamicho 6-chome, Takatsuki-shi, Osaka	Appointed April 1, 2005
		Registered April 1, 2005
Auditor	<u>Hiroyuki Himaki</u>	Appointed June 29, 2000
		Registered July 12, 2000
		Retired June 27, 2003
		Registered July 11, 2003
Auditor	<u>Norio Sasaki</u>	Appointed June 29, 2000
		Registered July 12, 2000
		Reappointed June 27, 2003
		Registered July 11, 2003
Auditor	<u>Norio Sasaki</u>	Retired March 31, 2005
		Registered April 1, 2005
		Appointed June 29, 2000
		Registered July 12, 2000
Auditor	<u>Shirou Tachikawa</u>	Retired June 27, 2003
		Registered July 11, 2003
		Appointed June 28, 2001
		Registered July 10, 2001
Auditor	<u>Toyomichi Ohtani</u>	Reappointed June 24, 2004
		Registered July 7, 2004
		Resigned March 31, 2005
		Registered April 1, 2005
Auditor	<u>Hideo Yamada</u>	Appointed June 28, 2001
		Registered July 10, 2001
		Reappointed June 24, 2004
		Registered July 7, 2004
Auditor	<u>Kenichirou Saitou</u>	Appointed June 27, 2003
		Registered July 11, 2003
Auditor	<u>Makoto Matsuo</u>	Appointed June 27, 2003
		Registered July 11, 2003
		Resigned June 24, 2004
		Registered July 7, 2004
Auditor	<u>Masaya Ishii</u>	Appointed April 1, 2005
		Registered April 1, 2005
Auditor	<u>Kanji Kobayashi</u>	Appointed April 1, 2005
		Registered April 1, 2005

PATENT

REEL: 017468 FRAME: 0333

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Branch office	1	<u>4-7, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo</u>	
		<u>5-7, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo</u>	Moved September 28, 2002
			Registered October 4, 2002
		5-9, Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo	Moved January 24, 2005
			Registered February 1, 2005
	2	<u>7-12, Kitahama 3-chome, Chuo-ku, Osaka</u>	
		6-5, Kawaramachi 3-chome, Chuo-ku, Osaka	Moved May 19, 2003
			Registered May 21, 2003
	3	9-1, Oodori-nishi 5-chome, Chuo-ku, Sapporo, Hokkaido	
	4	<u>10-21, Sakae 1-chome, Naka-ku, Nagoya</u>	
		1-36, Marunouchi 2-chome, Naka-ku, Nagoya	Moved April 1, 2005
			Registered April 1, 2005
	5	2-25, Oomachi 2-chome, Aoba-ku, Sendai, Miyagi	
	6	<u>18-25, Hakataeki-higashi 1-chome, Hakata-ku, Fukuoka</u>	
		2-1, Shimokawabata, Hakata-ku, Fukuoka	Moved April 1, 2005
			Registered April 1, 2005
	7	<u>5-6, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo</u>	
		<u>5-9, Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo</u>	Moved January 31, 2005
			Registered February 1, 2005
		24-8, Higashiueno 5-chome, Taito-ku, Tokyo	Moved April 1, 2005
			Registered April 1, 2005
	8	<u>4-8, Kotobukicho 1-chome, Takamatsu-shi, Kagawa</u>	
		2-1, Sunport, Takamatsu-shi, Kagawa	Moved March 22, 2004
			Registered March 22, 2004
	9	<u>7-2, Otemachi 3-chome, Naka-ku, Hiroshima</u>	
		11-10, Otemachi 2-chome, Naka-ku, Hiroshima	Moved April 1, 2005
			Registered April 1, 2005

PATENT

REEL: 017468 FRAME: 0334

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

10 <u>287, Nanjing Donglu 3-duan, Taibei</u>	Abolished October 31, 2004 Registered November 1, 2004
11 <u>84-2, Ohtamachi 6-chome, Naka-ku, Yokohama</u> 2-1, Minatomirai 2-chome, Nishi-ku, Yokohama	Moved February 25 2003 Registered March 4, 2003
12 513, Akinono-cho, Nijo-sagaru, Karasuma-dori, Nakagyo-ku, Kyoto	
13 <u>5-6, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo</u> <u>5-9, Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo</u> 7-5, Sakuragicho 1-chome, Omiya-ku, Saitama	Moved January 31, 2005 Registered February 1, 2005 Moved April 1, 2005 Registered April 1, 2005
15 2-25, Oomachi 2-chome, Aoba-ku, Sendai, Miyagi	Established April 1, 2005 Registered April 1, 2005
16 24-8, Higashiueno 5-chome, Taito-ku, Tokyo	Established April 1, 2005 Registered April 1, 2005
17 6, Nakase 2-chome, Mihama-ku, Chiba	Established April 1, 2005 Registered April 1, 2005
18 5-9, Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo	Established April 1, 2005 Registered April 1, 2005
19 1-36, Marunouchi 2-chome, Naka-ku, Nagoya	Established April 1, 2005 Registered April 1, 2005
20 5-2, Hon-machi 1-chome, Kanazawa-shi, Ishikawa	Established April 1, 2005 Registered April 1, 2005
21 6-5, Kawaramachi 3-chome, Chuo-ku, Osaka	Established April 1, 2005 Registered April 1, 2005
22 1-7, Isobedori 3-chome, Chuo-ku, Kobe	Established April 1, 2005 Registered April 1, 2005
23 1-3, Shimo-ishii 1-chome, Okayama	Established April 1, 2005 Registered April 1, 2005
24 2-1, Shimokawabata, Hakata-ku, Fukuoka	Established April 1, 2005 Registered April 1, 2005

PATENT

REEL: 017468 FRAME: 0335

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Equity warrant	<p>First equity warrant</p> <p>Number of equity warrants:</p> <p><u>1410</u></p> <p><u>1365</u></p> <p>Changed July 31, 2005, and registered August 4, 2005</p> <p><u>1285</u></p> <p>Changed August 31, 2005, and registered September 7, 2005</p> <p>1165</p> <p>Changed September 30, 2005, and registered October 13, 2005</p> <p>Type and number of shares for equity warrants</p> <p><u>Common shares of the Company: 141,000 shares</u></p> <p><u>The number of shares of stock for one equity warrant (hereinafter referred to as the "number of granted shares") shall be 100 shares.</u></p> <p><u>In the event of a stock split or reverse stock split involving the common shares of stock of the Company, the number of granted shares shall be adjusted based on the following formula. Any fractional number of shares less than one share that will arise as a result of the adjustment shall be discarded.</u></p> <p><u>Number of granted shares after adjustment = number of granted shares before adjustment x ratio of stock split or reverse stock split</u></p> <p><u>When there is an unavoidable reason requiring the adjustment of the number of granted shares such as capital decrease, merger or company spin-off of the Company, the number of granted shares shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.</u></p> <p><u>Common shares of the Company: 136,500 shares</u></p> <p><u>The number of shares of stock for one equity warrant (hereinafter referred to as the "number of granted shares") shall be 100 shares.</u></p> <p><u>In the event of a stock split or reverse stock split involving the common shares of stock of the Company, the number of granted shares shall be adjusted based on the following formula. Any fractional number of shares less than one share that will arise as a result of the adjustment shall be discarded.</u></p> <p><u>Number of granted shares after adjustment = number of granted shares before adjustment x ratio of stock split or reverse stock split</u></p> <p><u>When there is an unavoidable reason requiring the adjustment of the number of granted shares such as capital decrease, merger or company spin-off of the Company, the number of granted shares shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.</u></p> <p>Changed July 31, 2005, and registered August 4, 2005</p> <p><u>Common shares of the Company: 128,500 shares</u></p> <p><u>The number of shares of stock for one equity warrant (hereinafter referred to as the "number of granted shares") shall be 100 shares.</u></p> <p><u>In the event of a stock split or reverse stock split involving the common shares of stock of the Company, the number of granted shares shall be adjusted based on the following formula. Any fractional number of shares less than one share that will arise as a result of the adjustment shall be discarded.</u></p> <p><u>Number of granted shares after adjustment = number of granted shares before adjustment x ratio of stock split or reverse stock split</u></p> <p><u>When there is an unavoidable reason requiring the adjustment of the number of granted shares such as capital decrease, merger or company spin-off of the Company, the number of granted shares shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.</u></p> <p>Changed August 31, 2005, and registered September 7, 2005</p>
----------------	--

PATENT

REEL: 017468 FRAME: 0336

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Common shares of the Company: 116,500 shares

The number of shares of stock for one equity warrant (hereinafter referred to as the "number of granted shares") shall be 100 shares.

In the event of a stock split or reverse stock split involving the common shares of stock of the Company, the number of granted shares shall be adjusted based on the following formula. Any fractional number of shares less than one share that will arise as a result of the adjustment shall be discarded.

Number of granted shares after adjustment = number of granted shares before adjustment x ratio of stock split or reverse stock split

When there is an unavoidable reason requiring the adjustment of the number of granted shares such as capital decrease, merger or company spin-off of the Company, the number of granted shares shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.

Changed September 30, 2005, and registered October 13, 2005

Issue price of one equity warrant

Free

Amount of money to be paid at the time of the exercise of each equity warrant

The amount of money to be paid at the time of the exercise of each equity warrant shall be the amount obtained by multiplying the number of granted shares by the amount of money to be paid for one share to be issued or transferred through the exercise of each equity warrant (hereinafter referred to as the "exercise price").

The exercise price shall be the average of the closing prices (hereinafter referred to as the "closing price") of ordinary transactions of the Company's common shares at the Tokyo Stock Exchange for the days (excluding days when no transactions were carried out) of the month preceding the month that includes the date of issue of equity warrants (hereinafter referred to as the "issuing date"). Any fractional number of less than one yen shall be rounded up to one yen. However, if the exercise price is lower than the closing price on the issuing date (if there was no closing price on the issuing date, it shall be the closing price on the immediately preceding date), the said closing price shall become the exercise price.

When the Company issues new common shares or disposes of treasury stock at a price lower than market price (with the exception of the exercise of equity warrants and the conversion of convertible bonds based on the Commercial Code before the enforcement of the Law for Partial Amendment of the Commercial Code, etc. (No. 128 law of 2001)), the exercise price shall be adjusted based on the following formula. Any fractional number of less than one yen arising from the adjustment shall be rounded up to one yen.

Exercise price after adjustment = exercise price before adjustment x (number of already issued shares + number of newly issued shares x amount of payment per share / market price) / (number of already issued shares + number of newly issued shares)

The "number of already issued shares" used for the above formula shall be the number of shares obtained by deducting the number of treasury stock held by the Company from the number of outstanding shares of the Company. When treasury stock is disposed of, the "number of newly issued shares" shall be read as the "number of disposed treasury shares." In the event of a stock split or reverse stock split of the common shares of the Company on or after the issuing date, the exercise price shall be adjusted proportionately based on the ratio of the stock split or reverse

PATENT

REEL: 017468 FRAME: 0337

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

	<p>stock split. Any fractional number of less than one yen arising from the adjustment shall be rounded up to one yen.</p> <p>When there is an unavoidable reason requiring the adjustment of the exercise price such as capital decrease, merger or company spin-off of the Company on and after the issuing date, the exercise price shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.</p> <p>Period for the exercise of equity warrants: From July 1, 2005 to June 27, 2013</p> <p>Conditions for the exercise of equity warrants (excluding the amount of payment and period for exercise): The partial exercise of each equity warrant shall not be allowed.</p> <p>Reasons for the Company's cancellation of equity warrants and conditions for cancellation:</p> <p>(i) When a proposal for the approval of a merger agreement under which the Company will not be the surviving company is approved at the general shareholders meeting of the Company, or a proposal for the approval of a stock exchange agreement or stock transfer based on which the Company will become a wholly-owned subsidiary is approved at the general shareholders meeting of the Company, the Company may cancel the equity warrants without consideration.</p> <p>(ii) The Company may cancel without consideration equity warrants acquired and held by the Company which were not yet exercised.</p> <p style="text-align: right;">Registered July 11, 2003</p>
	<p>Second equity warrant</p> <p>Number of equity warrants: 1470</p> <p>Type and number of shares for equity warrants Common shares of the Company: 147,000 shares</p> <p>The number of shares of stock for one equity warrant (hereinafter referred to as the "number of granted shares") shall be 100 shares.</p> <p>In the event of a stock split or reverse stock split involving the common shares of stock of the Company, the number of granted shares shall be adjusted based on the following formula. Any fractional number of shares less than one share that will arise as a result of the adjustment shall be discarded.</p> <p>Number of granted shares after adjustment = number of granted shares before adjustment x ratio of stock split or reverse stock split</p> <p>When there is an unavoidable reason requiring the adjustment of the number of granted shares such as capital decrease, merger or company spin-off of the Company, the number of granted shares shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.</p> <p>Issue price of one equity warrant Free</p> <p>Amount of money to be paid at the time of the exercise of each equity warrant</p> <p>The amount of money to be paid at the time of the exercise of each equity warrant shall be the amount obtained by multiplying the number of granted shares by the amount of money to be paid for one share to be issued or transferred through the exercise of each equity warrant (hereinafter referred to as the "exercise price").</p> <p>The exercise price shall be the average of the closing prices (hereinafter referred to as the "closing price") of ordinary transactions of the Company's common shares at the Tokyo Stock Exchange for the days</p>

PATENT

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

(excluding days when no transactions were carried out) of the month preceding the month that includes the date of issue of equity warrants (hereinafter referred to as the "issuing date"). Any fractional number of less than one yen shall be rounded up to one yen. However, if the exercise price is lower than the closing price on the issuing date (if there was no closing price on the issuing date, it shall be the closing price on the immediately preceding date), the said closing price shall become the exercise price.

When the Company issues new common shares or disposes of common treasury stock at a price lower than the market price on or after the issuing date (with the exception of the exercise of equity warrants, the conversion of convertible bonds based on the Commercial Code before the enforcement of the Law for Partial Amendment of the Commercial Code, etc. (No. 128 law of 2001) and the transfer of treasury stock based on the provision of Article 221-2 (request for sale of shares that are less than the number of shares in one stock trade unit) of the Commercial Code), the exercise price shall be adjusted based on the following formula. Any fractional number of less than one yen arising from the adjustment shall be rounded up to one yen.

Exercise price after adjustment = exercise price before adjustment x (number of already issued shares + number of newly issued shares x amount of payment per share / market price) / (number of already issued shares + number of newly issued shares)

The "number of already issued shares" used for the above formula shall be the number of shares obtained by deducting the number of treasury stock held by the Company from the number of outstanding shares of the Company. When treasury stock is disposed of, the "number of newly issued shares" shall be read as the "number of disposed treasury shares." In the event of a stock split or reverse stock split of the common shares of the Company on or after the issuing date, the exercise price shall be adjusted proportionately based on the ratio of the stock split or reverse stock split. Any fractional number of less than one yen arising from the adjustment shall be rounded up to one yen.

When there is an unavoidable reason requiring the adjustment of the exercise price such as capital decrease, merger or company spin-off of the Company on and after the issuing date, the exercise price shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.

Period for the exercise of equity warrants:

From July 1, 2006 to June 24, 2014

Conditions for the exercise of equity warrants (excluding the amount of payment and period for exercise):

The partial exercise of each equity warrant shall not be allowed.

Reasons for the Company's cancellation of equity warrants and conditions for cancellation:

(i) When a proposal for the approval of a merger agreement under which the Company will not be the surviving company is approved at the general shareholders meeting of the Company, or a proposal for the approval of a stock exchange agreement or stock transfer based on which the Company will become a wholly-owned subsidiary is approved at the general shareholders meeting of the Company, the Company may cancel the equity warrants without consideration.

(ii) The Company may cancel without consideration equity warrants acquired and held by the Company which were not yet exercised.

Registered July 7, 2004

PATENT

REEL: 017468 FRAME: 0339

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

	<p>Equity warrants issued in August 2005</p> <p>Number of equity warrants: 1048</p> <p>Type and number of shares for equity warrants Common shares of the Company: 104,800 shares</p> <p>The number of shares of stock for one equity warrant (hereinafter referred to as the "number of granted shares") shall be 100 shares.</p> <p>In the event of a stock split or reverse stock split involving the common shares of stock of the Company, the number of granted shares shall be adjusted based on the following formula. Any fractional number of shares less than one share that will arise as a result of the adjustment shall be discarded.</p> <p>Number of granted shares after adjustment = number of granted shares before adjustment x ratio of stock split or reverse stock split</p> <p>When there is an unavoidable reason requiring the adjustment of the number of granted shares such as capital decrease, merger or company spin-off of the Company, the number of granted shares shall be reasonably adjusted in consideration of the conditions of capital decrease, merger or company spin-off, etc.</p> <p>Issue price of one equity warrant Free</p> <p>Amount of money to be paid at the time of the exercise of each equity warrant The amount of money to be paid at the time of exercise of each equity warrant shall be calculated by multiplying one yen, namely the amount paid per share to be issued or transferred with the exercise of each equity warrant, by the number of shares granted.</p> <p>Period for the exercise of equity warrants: From September 1, 2005 to June 24, 2025</p> <p>Conditions for the exercise of equity warrants (excluding the amount of payment and period for exercise):</p> <ol style="list-style-type: none"> (i) A person who holds equity warrants may exercise them only for ten years from the day after the person has relinquished both positions as a director and an executive officer of the Company (hereinafter referred to as the "exercise commencement date"). (ii) Notwithstanding the provision in (i) above, in the case of a) or b) described below, a person who holds equity warrants may exercise them only for the period set out in a) or b). <ol style="list-style-type: none"> a) If the exercise commencement date of the person who holds equity warrants does not fall by June 24, 2024: From June 25, 2024 to June 24, 2025 b) Irrespective of whether it takes place before or after the exercise commencement date, if a merger agreement in which the Company is not the surviving corporation or if a bill of a stock exchange contract or a stock transfer in which that the Company becomes a wholly-owned subsidiary is approved at a general meeting of shareholders of the Company: For 15 days from the day after said date of approval (iii) The partial exercise of each equity warrant shall not be allowed. <p>Reasons for the Company's cancellation of equity warrants and conditions for cancellation:</p> <ol style="list-style-type: none"> (i) If a person who holds equity warrants is unable to exercise all or part of the equity warrants, the Company may retire them without compensation. (ii) The Company may cancel without consideration equity warrants acquired and held by the Company.
--	--

Registered September 7, 2005

PATENT

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Convertible corporate bond	<p><u>Third unsecured convertible corporate bond</u></p> <p><u>Total amount of convertible bonds</u></p> <p><u>¥14,921,000,000</u></p> <p><u>¥14,915,000,000</u></p> <p>Changed April 30, 2001, and registered May 9, 2001</p> <p><u>¥14,913,000,000</u></p> <p>Changed April 30, 2002, and registered May 10, 2002</p> <p><u>¥14,911,000,000</u></p> <p>Changed May 31, 2002, and registered June 12, 2002</p> <p><u>¥14,903,000,000</u></p> <p>Changed December 30, 2002, and registered January 14, 2003</p> <p><u>Conditions for conversion:</u></p> <p><u>The issue price per share of the shares (the "conversion price") issued through conversion shall be decided as shown in (1) below, and the number of shares to be issued through conversion shall be as shown below. However, conversion shall not be requested for part of the face value of these bonds and interest.</u></p> <p><u>Number of shares = total of the face values of these bonds presented by each bond holder for the request of a conversion / conversion price</u></p> <p><u>In this event, if any fractional number of shares less than one share is created, the amount of the face value of bonds equivalent to the fractional number of shares shall be redeemed at a rate of 100 yen for the face value of 100 yen.</u></p> <p><u>(1) Conversion price: 4413 yen</u></p> <p><u>(2) Adjustment of the conversion price</u></p> <p><u>If the company issues new shares at a paid amount which is lower than market price after the issue of these bonds, the conversion price shall be adjusted based on the following formula.</u></p> <p><u>Conversion price after adjustment = conversion price before adjustment x (number of already issued shares + number of newly issued shares x amount of payment per share / market price) / (number of already issued shares + number of newly issued shares)</u></p> <p><u>The conversion price shall also be adjusted in the event of a stock dividend, free issue and stock split or reverse stock split. When, in the event of the issue of registered par value common shares of the company through conversion, the conversion price after adjustment is lower than the par value of the registered par value common shares of the company, the par value shall become the conversion price.</u></p> <p><u>Details of shares to be issued through conversion:</u></p> <p><u>Registered par value common shares of the company (par value per share: 50 yen)</u></p> <p><u>However, if the company decides that shares to be issued through the conversion of these bonds should be registered non-par-value common shares, the shares shall be registered non-par-value common shares of the company.</u></p> <p><u>Period for the request of conversion:</u></p> <p><u>From September 1, 1987 to December 30, 2002</u></p> <p><u>Amount of each convertible bond:</u></p> <p><u>One million yen</u></p> <p><u>Amount of payment for each convertible bond:</u></p> <p><u>Full amount</u></p> <p><u>These bonds may be converted into shares.</u></p> <p><u>Expiration of the period for the request of conversion on December 30, 2002</u></p> <p>Registered January 14, 2003</p>
----------------------------	---

PATENT

REEL: 017468 FRAME: 0341

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

	Yen-denominated convertible bond to mature in 2014
	Total amount of convertible bonds:
	<u>¥18,880,000,000</u>
	<u>¥18,680,000,000</u>
	Changed May 31, 1999, and registered June 14, 1999
	<u>¥17,690,000,000</u>
	Changed June 30, 1999, and registered July 12, 1999
	<u>¥11,230,000,000</u>
	Changed July 31, 1999, and registered August 10, 1999
	<u>¥10,540,000,000</u>
	Changed August 31, 1999, and registered September 13, 1999
	<u>¥9,650,000,000</u>
	Changed October 31, 1999, and registered November 12, 1999
	<u>¥9,440,000,000</u>
	Changed November 30, 1999, and registered December 13, 1999
	<u>¥9,220,000,000</u>
	Changed December 31, 1999, and registered January 14, 2000
	<u>¥9,180,000,000</u>
	Changed January 31, 2000, and registered February 14, 2000
	<u>¥8,390,000,000</u>
	Changed February 29, 2000, and registered March 14, 2000
	<u>¥8,150,000,000</u>
	Changed April 30, 2000, and registered May 12, 2000
	<u>¥8,140,000,000</u>
	Changed May 31, 2000, and registered June 13, 2000
	<u>¥7,510,000,000</u>
	Changed July 31, 2000, and registered August 8, 2000
	<u>¥7,290,000,000</u>
	Changed August 31, 2000, and registered September 11, 2000
	<u>¥6,640,000,000</u>
	Changed November 30, 2000, and registered December 8, 2000
	<u>¥6,610,000,000</u>
	Changed December 31, 2000, and registered January 12, 2001
	<u>¥6,600,000,000</u>
	Changed January 31, 2001, and registered February 8, 2001
	<u>¥6,500,000,000</u>
	Changed February 28, 2002, and registered March 11, 2002
	<u>¥6,480,000,000</u>
	Changed May 31, 2002, and registered June 12, 2002
	<u>¥6,470,000,000</u>
	Changed April 30, 2004, and registered May 13, 2004
	<u>¥5,820,000,000</u>
	Changed October 31, 2004, and registered November 10, 2004
	<u>¥5,020,000,000</u>
	Changed January 31, 2005, and registered February 8, 2005
	<u>¥4,490,000,000</u>
	Changed April 30, 2005 and registered May 13, 2005
	<u>¥3,740,000,000</u>
	Changed June 30, 2005, and registered July 12, 2005
	<u>¥30,000,000</u>
	Changed September 30, 2005, and registered October 13, 2005

PATENT

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

Conditions for conversion:

These bonds may be converted into par value common shares of the Company at a rate of one par value common share of the Company for the following conversion price, based on the face amount of these bonds:

However, any fractional number of shares less than one share created at the time of conversion shall be discarded, and no adjustment using cash shall be made.

a. The initial conversion price shall be 1,979 yen per share.

b. Revision of the conversion price

When an amount obtained by multiplying the average closing price for 30 consecutive business days starting from 45 consecutive business days in which there is a closing price of ordinary transactions of the Company's par value common shares on the Tokyo Stock Exchange before March 31, 1998, March 31, 2004 and March 31, 2009, respectively, (hereinafter respectively referred to as the "determination date") by 1.025 (any fraction of less than one yen shall be rounded up to one yen) is lower by one yen or more than the conversion price effective on each determination date, on and after April 22, 1998, April 22, 2004, and April 22, 2009 (hereinafter respectively referred to as the "effective date"), respectively, the conversion price shall be changed to each amount calculated as above (subject, however, to the adjustment set out in c. below, which took effect between the determination date and a date prior to the effective date). However, as a result of the adjustment, the conversion price shall not be lowered to less than 50% of the initial conversion price (however, if adjusted as set out in c. below, it shall be the amount after adjustment). If the adjusted conversion price is less than 50% of the initial conversion price, the conversion price shall be the amount obtained by rounding up less than one yen of an amount equivalent to 50% of the conversion price to one yen.

c. Adjustment of conversion price

Where the Company issues new common shares at an amount for payment that is lower than the market price of the common shares of the Company after the issue of these bonds, the conversion price shall be adjusted based on the following formula:

Conversion price after adjustment = conversion price before adjustment
 $\times (\text{number of already issued shares} + \text{number of newly issued shares} \times \text{amount of payment per share} / \text{market price}) / (\text{number of already issued shares} + \text{number of newly issued shares})$

The conversion price shall be adjusted appropriately in the event of a stock split, reverse stock split, issue of convertible bonds or bonds with warrants at the initial conversion price, a warrant exercise price that is lower than the market price of the common shares of the Company, or in other certain cases; provided, however, that the conversion price shall not be lower than the par value of the common shares of the Company.

Details of shares to be issued through conversion:

Par value common shares of the Company (current par value per share: 50 yen)

Period for request of conversion:

From May 9, 1994 to close of business on March 24, 2014 (based on the time of a place where conversion is requested)

Amount of each convertible bond:

Ten million yen

PATENT**REEL: 017468 FRAME: 0343**

Astellas Pharma Inc.

Company number 0199-01-034966

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo

	Amount of payment for each convertible bond: Full amount These bonds may be converted into shares.
Company spin-off	Spinning-off into Zepharm Inc. at 7-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo on October 1, 2004 Registered October 1, 2004
	Spinning-off into Astellas Tokai Co., Ltd. at 2-154-13, Obuke, Nishine-cho, Iwate-gun, Iwate on April 1, 2005 Registered April 13, 2005
Merger	Merged Fujisawa Pharmaceutical Co., Ltd at 4-7, Doshomachi 3-chome, Chuo-ku Osaka Registered April 1, 2005
Matters concerning the registered record	Based on the provision of Paragraph 3 of the supplementary regulation of the 1989 Ministerial Ordinance No. 15 of the Ministry of Justice Transferred May 20, 1999

This is to certify that the above are all the matters that are recorded on the register that are not sealed.

October 24, 2005

Tokyo Legal Affairs Bureau

Registrar Motoyuki Ohba